SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-062659
Filing Date
2022-10-07
Accepted
2022-10-07 07:00:11
Documents
13
Period of Report
2022-10-06
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea166884-8k_nektarther.htm   iXBRL 8-K 28154
2 RULE 2.4 ANNOUNCEMENT ea166884ex99-1_nektarther.htm EX-99.1 14119
  Complete submission text file 0001213900-22-062659.txt   218416

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE nktr-20221007.xsd EX-101.SCH 3221
4 XBRL LABEL FILE nktr-20221007_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE nktr-20221007_pre.xml EX-101.PRE 22355
7 EXTRACTED XBRL INSTANCE DOCUMENT ea166884-8k_nektarther_htm.xml XML 3491
Mailing Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158
Business Address 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94158 4154825300
NEKTAR THERAPEUTICS (Filer) CIK: 0000906709 (see all company filings)

IRS No.: 943134940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-24006 | Film No.: 221299281
SIC: 2834 Pharmaceutical Preparations